Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data i

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

San Diego , California , United States , American , Luke Walker , Sumit Madan , Banner Md Anderson Cancer Center , Nasdaq , Ut Md Anderson Cancer Center , Harpoon Therapeutics Inc , American Society Of Hematology , Exchange Commission , American Society , Annual Meeting , Overall Response Rate , Very Good Partial Response , Cancer Center , Associate Professor , Chief Medical Officer , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic ,